Management of Metastatic Nonfunctional Pancreatic Neuroendocrine Tumor Abstract #750

Introduction: Nonfunctional NETs themselves present in generally two ways, either with symptoms caused by the tumor compression of other organs, or found by imaging test performed for other reasons.
Aim(s): To present treatment tactics in case of metastatic nonfunctional pNETS.
Materials and methods: A 30-year-old female noticed intensive pain in the upper abdomen after a delivery in November 2006. A pancreatic lesion occupying the whole gland, multiple liver metastases and enlarged retroperitoneal lymph nodes were revealed by CT. The tumor biopsy showed it to be a somatostatin-producing NET with Ki-67 1-2%. Biotherapy with somatostatin and interferon was administered. Six months later, interferon treatment was stopped because of its side effects. In August 2008, the patient got worse because of migrating joint pain. Examinations showed bone and lung metastases, and chemotherapy with streptozotocin and zoledronic acid were prescribed.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Ivan Vasiliev

To read results and conclusion, please login ...

Further abstracts you may be interested in

#61 Multiple tumors in patients with pancreatic neuroendocrine tumours: morphological and immunohistochemical characteristics
Introduction: Pancreatic islet cell tumors occur in 80% of patients with MEN 1. Tumors are often multicentric. They often produce multiple peptides and biogenic amines.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Prof Larisa Gurevich
#348 Management of Multiple Endocrine Neoplasia Type 1 in Patients with Pancreatic Neuroendocrine Tumors
Introduction: Screening for MEN-1 is an integral part of examination of patients with pNETs because revelation of this hereditary pathology radically influences tactics of treatment.
Conference:
Category: Basic
Presenting Author: Ivan Vasiliev
#546 Treatment of Malignant Neuroendocrine Tumors of the Hepatopancreatododenal Region
Introduction: The incidence of malignant NETs of the hepatopancreatoduodenal region is currently set at 10-15 cases per 100,000 people. Patient treatment and prognosis differ from those with adenocarcinoma.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Ivan Vasiliev
#2869 Sunitinib in Combination with Lanreotide for the Treatment of Pancreatic Neuroendocrine Tumors
Introduction: A 33-year-old patient with pancreatic neuroendocrine tumor (NET) G2 revealed progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal space 1.5 months after surgical treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Anna Kuznetsova
#2878 Surgical Management of Neuroendocrine Tumor-Associated Liver Metastases
Introduction: Liver metastasis is common among patients who suffer from neuroendocrine tumors (NETs). Radical surgery is the standard treatment whenever possible but there is still controversies concerning the treatment strategies such as resection of the primary, role of debulking surgery, liver transplantation (LT) and neoadjuvant or adjuvant therapies.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Aicha Bengueddach